Skip to Main Content

Latest News

Yale Cancer Center Faculty and Trainees Present at AACR Annual Meeting

The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Read more
  • YCC, Smilow Awardees Honored

    Yale Cancer Center annual Conclave in New Haven, March 26, 2024 include research and clinical awards. The four research awards are for: Clinical Cancer Research, Translational Science Research, Population Science Research, and Basic Cancer Research. Nine other awards are granted, including the Ruth McCorkle Oncology Advanced Practice Provider Award, the Class of '61 Cancer Research Awards, Clinical Excellence Award, Mentorship Excellence Award, Teaching Excellence Award, Service Excellence Award, Director's Awards, the Leadership in Diversity, Equity & Inclusion Award and the Lifetime Achievement Award.

    Read more
  • Katerina Politi, PhD, elected to AACR Board of Directors

    Katerina Politi, PhD, Professor of Pathology; Co-Leader, Cancer Signaling Networks; and Scientific Director for the Center for Thoracic Cancers, is one of five individuals newly elected to the American Association for Cancer Research (AACR) Board of Directors.

    Read more
  • Paul Calabresi, MD Memorial Lecture

    Last Friday during Yale Cancer Center Grand Rounds, we welcomed Pasi A. Jänne, MD, PhD, Director of the Lowe Center for Thoracic Oncology and Professor of Medicine, Harvard Medical School; David M. Livingston, MD, Chair at Dana-Farber Cancer Institute, as guest presenter of the Paul Calabresi, MD, Memorial Lectureship, hosted by Dr. Roy Herbst, Deputy Director of Yale Cancer Center and Smilow Cancer Hospital.

    Read more
  • Don’t take away critical surgery options from breast cancer patients

    DIEP (deep inferior epigastric perforator), in which abdominal tissue is transplanted to the chest without using abdominal muscle, may soon be less available. Why? The Centers for Medicare and Medicaid Services (CMS) is planning to eliminate the billing codes for this and other specialized breast reconstruction procedures on Dec. 31, 2024. This should not be the case: women facing breast cancer need all the best reconstruction options readily available. This is deeply personal for me.

    Source: The Hill
    Read more
  • Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

    Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC). Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge. Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.

    Source: ASCO Daily News
    Read more
Get RSS Feed